German medical technology company Biotronik has launched its Inventra HF-T implantable cardioverter defibrillator (ICD) in the US.

The device has been designed as a cardiac resynchronisation therapy defibrillator (CRT-D) to deliver ultra-high-energy measuring 42 joules (J) on the first shock to heart failure patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

An ICD is considered necessary for patients suffering from tachycardia (fast arrhythmias) which converts dangerous arrhythmias to a normal heart rhythm by triggering shocks to the heart.

Jersey Shore University Medical Center electrophysiologist Dr Mark Mascarenhas said: "For an increasing number of patients specifically those with larger cardiac anatomy and lower ejection fraction a shock that is higher than the standard 36-37 J may be needed to convert irregular arrhythmia.

"The sooner an effective shock can be delivered, the likelihood of survival increases for these patients.

See Also:

"With the availability of Inventra HF-T, more heart failure patients will be able to receive 42J energy delivered upon the first shock and, hence, receive life-saving therapy."

“For such patients, a CRT-D that delivers ultra-high energy on the first shock has a higher chance of converting the irregular arrhythmia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"With the availability of Inventra HF-T, more heart failure patients will be able to receive 42J energy delivered upon the first shock and, hence, receive life-saving therapy."

The new device is part of the Inventra 7 CRT-D series featuring Biotronik Home Monitoring, ProMRI, CLS, 45 J ultra-high energy and quadripolar LV pacing enabling multiple left-ventricular pacing and sensing configurations for CRT management, thereby offering a powerful therapy for patients at risk of high defibrillation thresholds (DFTs).

Image: Biotronik’s Inventra HF-T CRT device. Photo: courtesy of Biotronik.